West Pharmaceutical Services, Inc. (WST) Balance Sheet

The steady climb in retained earnings from roughly $3.7B to $4.8B over the ten-quarter window suggests profits are being retained and compounding the equity base. Stable absolute debt against a growing asset base implies leverage is falling in relative terms, which appears to reflect disciplined capital management. Investors should note that the reported figures do not separate organic equity growth from timing effects in quarterly earnings recognition.

A debt-to-equity ratio near 0.10 implies that lenders bear little of the company's capital structure, which suggests limited sensitivity to rising rates or refinancing windows. The flat debt balance across the period indicates no meaningful leverage expansion to fund growth or acquisitions. This profile suggests financial flexibility is high, though the figures alone do not reveal debt maturity terms or covenant structure.

A current ratio near 2.8 indicates current assets comfortably exceed current liabilities, which appears adequate to absorb working capital swings. Cash balances fluctuated between roughly $404M and $791M over the period, suggesting timing of collections and acquisition outflows drives much of the variation. Investors should monitor whether cash levels remain sufficient if the mid-2026 contract roll-off reduces inflows.

Stable goodwill suggests recent acquisition spending has not translated into large new intangible balances, which lowers near-term impairment risk. A flat PP&E base alongside the sharp decline in reported capex intensity raises the question of whether capacity is being maintained or whether the asset base is aging. Investors should consider how the capital expenditure reduction interacts with expanding biologics and GLP-1 demand.